Last update Feb. 16, 2022
Very Low Risk
Synthetic pethidine derivative and peripheral opioid agonist that inhibits intestinal motility and may reduce gastrointestinal secretions. Used in diarrhea and in the management of colostomies and ileostomies. Oral administration 3 to 5 times a day.
Excreted into breast milk in non-significant levels. (Nikodem 1992)
Its very low oral bioavailability (intestinal absorption practically nil) minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
No side effects have been reported in infants of mothers taking loperamide. (Schaefer 2015)
Indiscriminate use for treatment of gastroenteritis is not justified. Most acute diarrheic disorders are self-limijted conditions. WHO’s Oral Rehydration Solutions and appropriate nutritional support are recommended.
Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Hale acces.02/2022, LactMed acces.02/2022, Briggs 2015, Schaefer 2015, Chen 2010, Mahadevan 2006, Nice 2000, Hagemann 1998)
American Academy of Pediatrics: medication usually compatible with breastfeeding. (AAP 2001)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM